Login to Your Account



Merck, Vertex Hep C Drugs Are Likely Scene Changers

By Mari Serebrov


Tuesday, April 26, 2011
Although no protease inhibitor has yet to be approved for hepatitis C, the new class of drugs is already changing the landscape for hepatitis C virus (HCV) therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription